Overview

Vincristine is a vinca alkaloid derived from the periwinkle plant (Catharanthus roseus) that binds tubulin and prevents microtubule formation, arresting cells in metaphase and killing rapidly dividing cancer cells. In veterinary oncology it is one of the most widely used chemotherapy drugs and forms the “O” (Oncovin) in CHOP-style lymphoma protocols.

Vincristine is a hazardous cytotoxic drug and a severe vesicant. It must only be administered by oncology-trained veterinary staff with proper PPE, a clean IV catheter, and extravasation protocols in place. Intrathecal administration is universally fatal and has been responsible for multiple human deaths — vincristine must NEVER be given by any route other than IV.

Uses

  • Lymphoma — central component of CHOP and modified CHOP protocols in ferrets, dogs, and cats
  • Immune-mediated thrombocytopenia (IMT) in dogs — used as a single IV dose to release platelets and stimulate megakaryocytes
  • Canine transmissible venereal tumor (TVT) — usually curative as a single-agent therapy
  • Mast cell tumor (occasionally, in combination protocols)

In ferrets the primary indication is lymphoma, almost always as part of multi-agent chemotherapy.

Dosage

Only oncology-trained clinicians should prescribe or administer vincristine. Ferret dosing is extrapolated from feline protocols:

  • Typical ferret dose: approximately 0.025-0.1 mg/kg IV (published protocols vary widely; many use 0.07 mg/kg IV weekly during induction)
  • Given through a cleanly placed, patent IV catheter
  • Weekly dosing in the induction phase of modified CHOP, then rotating with cyclophosphamide and doxorubicin during maintenance
  • Volumes are tiny in a 1 kg ferret and must be compounded or drawn up with great precision
  • Dose reduction is indicated for severe neutropenia, GI toxicity, or peripheral neuropathy

Side Effects

Vincristine is generally considered one of the better-tolerated chemotherapy drugs in terms of bone marrow, but has unique toxicities:

  • Mild myelosuppression — less severe than cyclophosphamide or doxorubicin, though not negligible
  • Peripheral neuropathy — constipation, ileus, and rarely weakness; reflects microtubule disruption in peripheral nerves
  • GI toxicity — anorexia, vomiting, diarrhea, constipation, paralytic ileus
  • Severe extravasation injury — vincristine is one of the most damaging vesicants; leakage into tissue causes progressive necrosis that can require surgical debridement
  • Alopecia — minimal in ferrets
  • Hypersensitivity reactions — rare
  • SIADH-like syndrome — rare

Handling and Safety Warnings

  • NEVER ADMINISTER BY ANY ROUTE OTHER THAN IV. Intrathecal vincristine is uniformly fatal in any species. Pharmacy and clinic protocols should dilute vincristine in a minibag for infusion to prevent accidental intrathecal injection.
  • Cytotoxic hazard to humans. Vincristine is classified as a hazardous drug by NIOSH.
  • Chemotherapy PPE required: double nitrile gloves, gown, mask, eye protection
  • Prepare in a biological safety cabinet with closed-system transfer devices
  • Extravasation is an emergency. Hyaluronidase and warm compresses are the treatment of choice — the opposite approach from doxorubicin extravasation (which uses cold compresses). Oncology staff must know the difference before administering.
  • Post-treatment waste handling: wear gloves when handling urine, feces, vomit, litter, and bedding for at least 48-72 hours. Double-bag all waste.
  • Pregnant or breastfeeding women, women or partners trying to conceive, children, and immunocompromised individuals must not handle the drug or the patient’s waste.

Drug Interactions

  • L-asparaginase — give vincristine BEFORE asparaginase to avoid enhanced neurotoxicity
  • Itraconazole, ketoconazole — may increase vincristine toxicity (CYP3A inhibition)
  • Phenytoin — vincristine may reduce phenytoin levels
  • Other neurotoxic drugs — additive neuropathy
  • Live vaccines — avoid during chemotherapy

Contraindications

  • Pre-existing severe peripheral neuropathy or ileus
  • Active infection with severe neutropenia
  • Significant hepatic dysfunction (vincristine is hepatically cleared)
  • Known hypersensitivity
  • Pregnant handlers must not prepare or administer the drug

FAQs

Is vincristine safe in ferrets? When given by a veterinary oncology team using proper ferret doses and handling precautions, vincristine is a cornerstone of modern ferret lymphoma therapy. It is not a drug for general practice.

What if the drug leaks out of the vein? Extravasation is an emergency. Immediately stop the infusion, aspirate back what you can through the catheter, and treat with warm compresses and hyaluronidase according to your oncology team’s protocol.

Will my ferret lose its fur? Alopecia is minimal in ferrets; unlike humans, they typically retain most of their coat through treatment.

What should I watch for at home? Constipation, weakness, persistent vomiting, appetite loss, or any sign of infection (lethargy, fever, breathing changes) — all warrant immediate contact with your oncology team.

Why can it only be given IV? Accidental spinal (intrathecal) vincristine is universally fatal. This is why syringes of vincristine are now supplied in minibags in human hospitals — to eliminate any possibility of the wrong route. In veterinary practice it must always be given through a clean, patent IV line.